Advances in breast cancer treatment: The emerging role of ixabepilone

Expert Review of Anticancer Therapy

Volumn 10, Issue 1, 2010, Pages 23-32

  Frye, Debra K ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Anthracyclines; Chemotherapy resistance; Epothilone; Ixabepilone; Metastatic breast cancer; Microtubule stabilizing agent; Supportive care; Taxane

Indexed keywords

ALPHA TOCOPHEROL; ANALGESIC AGENT; ANTIHISTAMINIC AGENT; CALCIUM; CAPECITABINE; CARBAMAZEPINE; CARBOPLATIN; CISPLATIN; CREMOPHOR; CYCLOPHOSPHAMIDE; DESIPRAMINE; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; FLUOXETINE; GEMCITABINE; GLUTAMINE; IXABEPILONE; MAGNESIUM; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; OXALIPLATIN; PACLITAXEL; RANITIDINE; TRASTUZUMAB; UNINDEXED DRUG; VALPROIC ACID;

ACUPUNCTURE; ADD ON THERAPY; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BALNEOTHERAPY; BONE MARROW SUPPRESSION; BREAST CANCER; BREAST METASTASIS; BREAST SURGERY; BRONCHOSPASM; BURNING SENSATION; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DISEASE FREE SURVIVAL; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG SAFETY; DRUG SENSITIVITY; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ELECTROSTIMULATION; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL SYMPTOM; HAND FOOT SYNDROME; HOT FLUSH; HUMAN; HYPERESTHESIA; HYPESTHESIA; INFECTION; KINESIOTHERAPY; LEUKOPENIA; MAGNETOTHERAPY; MASSAGE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; OVERALL SURVIVAL; PARESTHESIA; PATIENT EDUCATION; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RASH; REVIEW; SENSORY NEUROPATHY; SINGLE DRUG DOSE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; DRUG APPROVAL; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; HUMANS; NEOPLASM METASTASIS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 74749108019     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.158     Document Type: Review

References (47)

1. American Cancer Society. Cancer Facts and Figures, 2008. American Cancer Society Inc., Atlanta, GA, USA (2008).
2. American Cancer Society. Breast Cancer Facts and Figures, 2007-2008. American Cancer Society Inc., Atlanta, GA, USA (2008).
3. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J. Clin. 58(2), 71-96 (2008).
4. Bergstralh DT, Ting JP. Microtubule stabilizing agents: their molecular signaling consequences and the potential for enhancement by drug combination. Cancer Treat. Rev. 32(3), 166-179 (2006).
5. HERCEPTIN® (trastuzumab) intravenous infusion, package insert. Genentech, Inc., CA, USA (2008).
6. Gianni L, Munzone E, Capri G et al. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines. J. Natl Cancer Inst. 87(15), 1169-1175 (1995).
7. Jones SE, Erban J, Overmoyer B et al. Randomized Phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J. Clin. Oncol. 23(24), 5542-5551 (2005).
8. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group. J. Clin. Oncol. 17(5), 1413-1424 (1999).
9. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 48, 353-374 (1997).
10. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst. Rev. 4, CD004421 (2007).
11. Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol® ). J. Biol. Chem. 272(4), 2534-2541 (1997).
12. Lee FY, Borzilleri R, Fairchild CR et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin. Cancer Res. 7(5), 1429-1437 (2001).
13. Kamath K, Jordan MA. Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest. Cancer Res. 63(18), 6026-6031 (2003).
14. Chou TC, Zhang XG, Balog A et al. Desoxyepothilone B: an efficacious microtubule-targeted antitumor agent with a promising in vivo profile relative to epothilone B. Proc. Natl Acad. Sci. USA 95(16), 9642-9647 (1998).
15. Altmann KH. Epothilone B and its analogs - a new family of anticancer agents. Mini Rev. Med. Chem. 3(2), 149-158 (2003).
16. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. 22(10), 2015-2025 (2004). • Overview of the epothilone class, including their differences from taxanes.
17. Altmann KH, Wartmann M, O'Reilly T. Epothilones and related structures - a new class of microtubule inhibitors with potent in vivo antitumor activity. Biochim. Biophys. Acta 1470(3), M79-M91 (2000).
18. Pivot X, Dufresne A, Villanueva C. Efficacy and safety of ixabepilone, a novel epothilone analogue. Clin. Breast Cancer 7(7), 543-549 (2007).
19. Abraham J, Agrawal M, Bakke S et al. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J. Clin. Oncol. 21(9), 1866-1873 (2003).
20. Mani S, McDaid H, Hamilton A et al. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin. Cancer Res. 10(4), 1289-1298 (2004).
21. IXEMPRA® Kit (ixabepilone) for injection, package insert. Bristol-Myers Squibb NJ, USA (2009). •• IXEMPRA® package insert provides detailed guidelines regarding percentage dose reductions and discontinuations in the event of toxicities (according to grade and duration).
22. Low JA, Wedam SB, Lee JJ et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J. Clin. Oncol. 23(12), 2726-2734 (2005).
23. Denduluri N, Low JA, Lee JJ et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J. Clin. Oncol. 25(23), 3421-3427 (2007).
24. Denduluri N, Lee JJ, Walshe J et al. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest. New Drugs 25(1), 63-67 (2007).
25. Roché H, Yelle L, Cognetti F et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J. Clin. Oncol. 25(23), 3415-3420 (2007).
26. Thomas E, Tabernero J, Fornier M et al. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J. Clin. Oncol. 25(23), 3399-3406 (2007).
27. Perez EA, Lerzo G, Pivot X et al. Efficacy and safety of ixabepilone (BMS-247550) in a Phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J. Clin. Oncol. 25(23), 3407-3414 (2007).
28. Baselga J, Zambetti M, Llombart-Cussac A et al. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J. Clin. Oncol. 27(4), 526-534 (2009). •• Supported the approval of ixabepilone monotherapy in this indication.
29. Bunnell CA, Klimovsky J, Thomas E. Final efficacy results of a Phase I/II trial of ixabepilone in combination with capecitabine in patients with metastatic breast cancer (MBC) previously treated with a taxane and an anthracycline. J. Clin. Oncol. 24(18 Suppl.), (2006) (Abstract 10511).
30. Bunnell C, Vahdat L, Schwartzberg L et al. Phase I/II study of ixabepilone plus capecitabine in anthracycline-pretreated/ resistant and taxane-resistant metastatic breast cancer. Clin. Breast Cancer 8(3), 234-241 (2008).
31. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 25(33), 5210-5217 (2007). •• Supported the approval of ixabepilone plus capecitabine in this indication.
32. Hortobagyi G, Perez E, Vrdoljak C et al. Analysis of overall survival (OS) among patients (pts) with metastatic breast cancer (MBC) receiving either ixabepilone (I) plus capecitabine (C) or C alone: results from two randomized Phase III trials. Proc. Am. Soc. Clin. Oncol. (Breast Cancer Symposium) (2008) (Abstract 186). •• Presented updated survival data from [31], along with survival data from the Phase III confirmatory trial.
33. Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 26(13), 2223 (2008).
34. Conte P, Roche H, Perez E et al. Ixabepilone plus capecitabine improves overall survival in symptomatic patients with metastatic breast cancer previously treated with anthracycline and taxane in 2 large Phase III studies. Cancer Res. 69(2 Suppl.), (2009) (Abstract 6114). • This subpopulation experienced an overall survival benefit, a rarity in metastatic breast cancer studies, associated with ixabepilone plus capecitabine.
35. Sève P, Dumontet C. Is class III β-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9(2), 168-175 (2008).
36. Horak CE, Lee FY, Xu L, Galbraith S, Baselga J. High β-III tubulin expression in triple-negative (TN) breast cancer (BC) subtype and correlation to ixabepilone response: a retrospective analysis. J. Clin. Oncol. 27(15 Suppl.), (2009) (Abstract 3587). • Retrospective study of the ixabepilone neoadjuvant data.
37. Rugo HS, Roche H, Thomas E et al. Ixabepilone plus capecitabine vs capecitabine in patients with triple negative tumors: a pooled analysis of patients from two large Phase III clinical studies. Cancer Res. 69(2 Suppl.), (2009) (Abstract 3057).
38. Lee JJ, Swain SM. Peripheral neuropathy induced by microtubule- stabilizing agents. J. Clin. Oncol. 24(10), 1633-1642 (2006).
39. Perez E, Pivot X, Vrdoljak E, Sparano JA, Vogel C, Peck R. A prospective characterization of the resolution of ixabepilone induced peripheral neuropathy: data from a large registrational program in patients with metastatic breast cancer. Cancer Res. 69(2 Suppl.), (2009) (Abstract 6140). • Revealed that ixabepilone-induced peripheral neuropathy is reversible to baseline or grade 1 in a matter of weeks.
40. Armstrong T, Almadrones L, Gilbert MR. Chemotherapy-induced peripheral neuropathy. Oncol. Nurs. Forum 32(2), 305-311 (2005).
41. Wickham R. Chemotherapy-induced peripheral neuropathy: a review and implications for oncology nursing practice. Clin. J. Oncol. Nurs. 11(3), 361-376 (2007).
42. Visovsky C, Collins A, Abbott L, Aschenbrenner J, Hart C. Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. Clin. J. Oncol. Nurs. 11(6), 901-913 (2007).
43. Martin V. Arthralgias and myalgias. In: Cancer Symptom Management (Third Edition). Yarbro CH, Frogge MH, Goodman M (Eds.). Jones and Bartlett, MA, USA 17-24 (2003).
44. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 14(2), 85-93 (2008).
45. Richardson G, Dobish R. Chemotherapy induced diarrhea. J. Oncol. Pharm. Practice 13(4), 181-198 (2007).
46. Barsevick A, Newhall T, Brown S. Management of cancer-related fatigue. Clin. J. Oncol. Nurs. 12(5 Suppl.), 21-25 (2008).
47. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology™. Breast Cancer V.1.2010 www.nccn.org/professionals/physician- gls/PDF/breast.pdf (Accessed 7 December 2009).